Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diabetes and Migration.
Şat S, Aydınkoç-Tuzcu K, Berger F, Barakat A, Danquah I, Schindler K, Fasching P. Şat S, et al. Exp Clin Endocrinol Diabetes. 2023 Jun;131(6):319-337. doi: 10.1055/a-1946-3878. Epub 2023 Jun 14. Exp Clin Endocrinol Diabetes. 2023. PMID: 37315566 No abstract available.
[Migration and diabetes (Update 2019)].
Aydinkoc-Tuzcu K, Schindler K, Sat S, Berger F, Ludvik B, Fasching P. Aydinkoc-Tuzcu K, et al. Among authors: sat s. Wien Klin Wochenschr. 2019 May;131(Suppl 1):229-235. doi: 10.1007/s00508-019-1446-0. Wien Klin Wochenschr. 2019. PMID: 30980158 Review. German.
Diabetes and Migration.
Şat S, Aydınkoç-Tuzcu K, Berger F, Barakat A, Schindler K, Fasching P. Şat S, et al. Exp Clin Endocrinol Diabetes. 2021 Aug;129(S 01):S106-S118. doi: 10.1055/a-1284-6778. Epub 2021 Apr 14. Exp Clin Endocrinol Diabetes. 2021. PMID: 33853175 No abstract available.
[Diabetes and migration (update 2023)].
Aydınkoç-Tuzcu K, Şat S, Berger F, Barakat A, Danquah I, Schindler K, Fasching P. Aydınkoç-Tuzcu K, et al. Among authors: sat s. Wien Klin Wochenschr. 2023 Jan;135(Suppl 1):286-306. doi: 10.1007/s00508-023-02175-7. Epub 2023 Apr 20. Wien Klin Wochenschr. 2023. PMID: 37101050 German.
Correction: Diabetes und Migration (Update 2023).
Aydınkoç-Tuzcu K, Şat S, Berger F, Barakat A, Danquah I, Schindler K, Fasching P. Aydınkoç-Tuzcu K, et al. Among authors: sat s. Wien Klin Wochenschr. 2023 Jul;135(13-14):388. doi: 10.1007/s00508-023-02244-x. Wien Klin Wochenschr. 2023. PMID: 37401959 German. No abstract available.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.